Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients
This study is currently recruiting participants.
Verified July 2013 by The University of Texas Health Science Center at San Antonio
Information provided by (Responsible Party):
Gregory P. Swanson, MD, The University of Texas Health Science Center at San Antonio
First received: October 9, 2012
Last updated: July 10, 2013
Last verified: July 2013
The purpose of the study is to (1) to determine the rate of PSA decline (the number declining). Tissue will be obtained for ancillary studies and (2) to determine the number of patients with a PSA decline to <1.0 ng/ml at 3 months in patients receiving Nexrutine® with standard radiation therapy. The Secondary Objective is to confirm the tolerability of this regimen. The Third Objective (Ancillary studies) is To evaluate the molecular response of Nexrutine®. Molecular response is defined as changes in the molecular pathways.
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Phase II Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients Undergoing Surgery or Radiation Therapy
Primary Outcome Measures:
- PSA (Prostate Specific Antigen) [ Time Frame: 3 months post surgery or end of radiation treatment ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||June 2014 (Final data collection date for primary outcome measure)
Surgery Group: Nexrutine 500mg by mouth, three times per day, given prior to surgery.
Radiation Group: Nexrutine 500mg by mouth, three times per day, given prior to and during radiation treatment.
Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
- bark extract of Phellodendron amurense
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Have a histologic diagnosis of prostate cancer (in more than 1 core) with one of the following:
- Gleason > 6,
- Unilateral Gleason 6 in ≥ 3 cores,
- bilateral Gleason 6,
- PSA > 10.0 ng/ml.
- Age ≥18 years.
- Has an ECOG Performance Status 0-2 or Karnofsky 60-100.
- Has the following laboratory values at study entry: absolute neutrophil count (ANC) ≥ 1,500 cells/μL; platelet count ≥ 100,000 cells/μL; hemoglobin ≥ 9 g/dL; total serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); ALT and AST ≤ 1.5 x institutional ULN if alkaline phosphatase is ≤ULN creatinine and BUN ≤ 1.5 x institutional upper limit of normal (ULN)
- Signed informed consent
- No new, undiagnosed bone pain or has a negative bone scan. (within 2 months of consent) If there is no bone pain, then a bone scan is not required.
- Has documented metastatic disease.
- Has received a prior chemotherapy or androgen ablation.
- Has received prior immunotherapy.
- Has been previously treated with Strontium, Samarium, other systemic radioisotopes or radiation therapy.
- Has diagnosis of congestive heart failure
- Currently taking anticoagulation medications, i.e., coumadin or heparin. Over the counter aspirin and ibuprofen are allowed.
- Is receiving any other investigational agents for cancer.
- Has a history of other malignancy within the last 5 years, which could affect the diagnosis or assessment of prostate cancer.
- Has a serious intercurrent illness with a life expectancy of less than 5 years.
- Has a concomitant medical, psychological, or social circumstance, which would interfere with compliance with the protocol treatment and follow-up.
- Use of any herbal or alternative regimens, which may have antineoplastic or hormonal activity (including but not limited to finasteride, dutasteride, Saw Palmetto, PC-SPES, shark cartilage, etc), is prohibited while receiving study treatment.
- Clinical stage T3 or T4 and PSA >10 ng/ml and Gleason > 8.
- Patient is to receive adjuvant androgen ablation with the radiation.
- EKG which shows a baseline QTc > 450 msec or ischemic changes. For ischemic changes, patient will be eligible if evaluated and cleared by internal medicine.
- Previous history of drug-induced QTc prolongation and/or concurrent treatment with medications that are known to produce or are suspected of QT prolongation.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01705652
|The University of Texas Health Science Center at San Antonio, study site: ALM VA Hospital
|San Antonio, Texas, United States, 78229 |
|Contact: Carol A. Jenkins, RN, MSN 210-450-5924 email@example.com |
|Contact: Sylvia E. Sluder 210-450-1863 firstname.lastname@example.org |
|Principal Investigator: Gregory P. Swanson, MD |
|Principal Investigator: William E. Jones, III, MD |
The University of Texas Health Science Center at San Antonio
||Gregory P. Swanson, MD
||The University of Texas Health Science Center at San Antonio
||William E. Jones, III, MD
||The University of Texas Health Science Center at San Antonio and ALM VA Hospital
No publications provided
||Gregory P. Swanson, MD, Clinical Professor, The University of Texas Health Science Center at San Antonio
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 9, 2012
||July 10, 2013
||United States: Food and Drug Administration
United States: Institutional Review Board
Keywords provided by The University of Texas Health Science Center at San Antonio:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 08, 2013
Genital Neoplasms, Male
Neoplasms by Site
Genital Diseases, Male